Published in Proc Soc Exp Biol Med on December 01, 1966
Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience. Br Med J (Clin Res Ed) (1983) 1.83
Microneutralization test for the determination of mumps antibody in vero cells. Appl Microbiol (1970) 1.61
Mumps virus replication in chick embryo lung cells: properties of ribonucleic acids in virions and infected cells. J Virol (1971) 1.43
Plaque formation by mumps virus and inhibition by antiserum. Appl Microbiol (1970) 1.17
The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence. J Virol (2007) 0.99
Evaluation of a neonatal rat model for prediction of mumps virus neurovirulence in humans. J Virol (2000) 0.98
Molecular biology, pathogenesis and pathology of mumps virus. J Pathol (2015) 0.95
Comparison of the neurovirulence of a vaccine and a wild-type mumps virus strain in the developing rat brain. J Virol (1998) 0.91
T-cell-mediated cytotoxic response to mumps virus in humans. Infect Immun (1980) 0.87
Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype. J Virol (2003) 0.87
Infection of mice, ferrets, and rhesus macaques with a clinical mumps virus isolate. J Virol (2013) 0.84
RNA virus reverse genetics and vaccine design. Viruses (2014) 0.82
Immunogenicity of novel mumps vaccine candidates generated by genetic modification. J Virol (2013) 0.78
Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response. J Virol (2015) 0.77
In vitro and in vivo growth alter the population dynamic and properties of a Jeryl Lynn mumps vaccine. Vaccine (2015) 0.77
Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes. Expert Rev Vaccines (2015) 0.75
Molecular determinants of plaque size as an indicator of dengue virus attenuation. Sci Rep (2016) 0.75
Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs. Vaccines (Basel) (2015) 0.75
Vaccination of school children with live mumps virus vaccine. Can Med Assoc J (1970) 0.75
Mumps prophylaxis. Can Med Assoc J (1967) 0.75
Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci U S A (1967) 7.65
Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum. Proc Natl Acad Sci U S A (1967) 4.82
Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med (1979) 3.89
Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. N Engl J Med (1967) 3.72
Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med (1984) 2.93
Multiple molecular species of interferons of mouse and of rabbit origin. Proc Soc Exp Biol Med (1966) 2.87
Protective efficacy of pneumococcal polysaccharide vaccines. JAMA (1977) 2.83
Physical, chemical and morphologic dimensions of human hepatitis A virus strain CR326 (38578). Proc Soc Exp Biol Med (1975) 2.59
Human hepatitis B vaccine from recombinant yeast. Nature (1984) 2.46
Specific immune adherence assay for human hepatitis A antibody application to diagnostic and epidemiologic investigations. Proc Soc Exp Biol Med (1975) 2.38
Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med (1978) 2.18
Vaccine against human hepatitis B. JAMA (1976) 2.10
Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage. Proc Natl Acad Sci U S A (1967) 2.02
Vaccine against human hepatitis B. 1976. JAMA (1996) 1.96
Inducers of interferon and host resistance. 3. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA). Proc Natl Acad Sci U S A (1967) 1.87
Measurement of immunity following live mumps (5 years), measles (3 years), and rubella (2 and one-half years) virus vaccines. Pediatrics (1972) 1.78
Live, attenuated mumps-virus vaccine. N Engl J Med (1968) 1.76
Studies in human subjects of polyvalent pneumococcal vaccines (39894). Proc Soc Exp Biol Med (1977) 1.74
Combined live measles, mumps, and rubella virus vaccines. JAMA (1969) 1.74
Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation. N Engl J Med (1967) 1.69
Inducers of interferon and host resistance, V. In vitro studies. Proc Natl Acad Sci U S A (1968) 1.68
A specific complement-fixation test for human hepatitis a employing CR326 virus antigen. Diagnosis and epidemiology. Proc Soc Exp Biol Med (1975) 1.64
Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog Med Virol (1966) 1.62
Follow-up surveillance for antibody in human subjects following live attenuated measles, mumps, and rubella virus vaccines. Proc Soc Exp Biol Med (1979) 1.47
Live attenuated rubella virus vaccines prepared in duck embryo cell culture. I. Development and clinical testing. JAMA (1968) 1.46
Development and evaluation of the Moraten measles virus vaccine. JAMA (1968) 1.45
Etiologic relationship of marmoset-propagated CR326 hepatitis A virus to hepatitis in man. Proc Soc Exp Biol Med (1973) 1.45
Live respiratory syncytial virus vaccine administered parenterally. Proc Soc Exp Biol Med (1978) 1.36
Inducers of interferon and host resistance. VI. Antiviral efficacy of poly I:C in animal models. Proc Soc Exp Biol Med (1969) 1.35
Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA (1984) 1.33
Enzyme-linked immunosorbent assay for measurement of antibodies against pneumococcal polysaccharide antigens: comparison with radioimmunoassay. J Clin Microbiol (1979) 1.31
Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA (1971) 1.31
Studies on induction of virus from adenovirus and SV40 hamster tumors 1. Chemical and physical agents. Proc Soc Exp Biol Med (1966) 1.26
Hyperpotentiation by synthetic double-stranded RNA of antibody responses to influenza virus vaccine in adjuvant 65. Proc Soc Exp Biol Med (1969) 1.26
Double-stranded RNAs (poly I:C) in the prevention of viral infections. Arch Intern Med (1970) 1.25
Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines. Pediatrics (1978) 1.25
Prospects for the use of double-stranded ribonucleic acid (poly I:C) inducers in man. J Infect Dis (1970) 1.24
A PROTECTIVE ANTISERUM AGAINST MOUSE PNEUMONITIS VIRUS. Science (1943) 1.24
Studies on induction of virus from adenovirus and SV40 hamster tumors 2. "Helper" viruses. Proc Soc Exp Biol Med (1966) 1.22
Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci (1977) 1.22
Rubella vaccination in adult females. N Engl J Med (1969) 1.21
Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis (1981) 1.20
Progress toward a live, attenuated human hepatitis A vaccine. Proc Soc Exp Biol Med (1982) 1.17
Interferon induction and utilization. J Cell Physiol (1968) 1.17
Further investigations of live respiratory syncytial virus vaccine administered parenterally. Proc Soc Exp Biol Med (1979) 1.16
Seroepidemiologic investigations of human hepatitis caused by A, B, and a possible third virus. Proc Soc Exp Biol Med (1976) 1.13
Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines. Proc Soc Exp Biol Med (1980) 1.11
Evidence for viral hepatitis other than type A or type B among persons in Costa Rica. N Engl J Med (1975) 1.10
Polyvalent pneumococcal polysaccharide vaccines. Bull World Health Organ (1978) 1.09
Clinical and laboratory investigations of monovalent and combined meningococcal polysaccharide vaccine, groups A and C. Proc Soc Exp Biol Med (1976) 1.09
Live attenuated mumps virus vaccine. II. Early clinical studies. Pediatrics (1967) 1.09
Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics (1975) 1.09
Herpes simplex vaccines. Cancer Res (1976) 1.08
The clinical application of adjuvant 65. Ann Allergy (1972) 1.07
Recovery of hepatitis agents in the marmoset from human cases occurring in Costa Rica. Proc Soc Exp Biol Med (1973) 1.06
Stability on storage at various temperatures of live measles, mumps and rubella virus vaccines in new stabilizer. J Biol Stand (1980) 1.05
Influence of polyamines on induction of interferon and resistance to viruses by synthetic polynucleotides. Proc Soc Exp Biol Med (1969) 1.04
New findings in live, attenuated hepatitis A vaccine development. J Med Virol (1986) 1.04
Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med (1979) 1.03
Influence of synthetic (poly I:C) and viral double-stranded ribonucleic acids on adenovirus 12 oncogenesis in hamsters. Proc Soc Exp Biol Med (1969) 1.03
Respiratory virus vaccines. II. Mycoplasma pneumoniae (Eaton agent) vaccines. Am Rev Respir Dis (1966) 0.99
Influence of size of individual homopolynucleotides on the physical and biological properties of complexed rIn:rCn (poly I:C). Proc Soc Exp Biol Med (1970) 0.98
Antibody response in man to Hong Kong influenza following 1967 formula influenza vaccine in adjuvant 65. Proc Soc Exp Biol Med (1969) 0.98
Pneumococcal vaccine: dose, revaccination, and coadministration with influenza vaccine. Proc Soc Exp Biol Med (1979) 0.98
Live, attenuated rubella-virus vaccine. N Engl J Med (1968) 0.97
New metabolizable immunologic adjuvant for human use. 5. Evaluation of highly purified influenza-virus vaccine in adjuvant 65. N Engl J Med (1967) 0.96
Comparison of neutralization and hemagglutination-inhibition techniques for measuring mumps antibody. Proc Soc Exp Biol Med (1967) 0.95
Clinical laboratory evaluation of rubella virus vaccine given to postpartum women without pregnancy preventive. Obstet Gynecol (1973) 0.95
New metabolizable immunologic adjuvant for human use. IX. Large-scale trials with multiple lots in different regimens. JAMA (1969) 0.94
Relationship of molecular size of rIn:rCn (poly I:C) to induction of interferon and host resistance. Proc Soc Exp Biol Med (1970) 0.94
Studies for safety of adjuvant 65. Ann Allergy (1972) 0.94
Induction of interferon in human subjects by poly I:C. Proc Soc Exp Biol Med (1971) 0.94
Suitability of the rufiventer marmoset as a host animal for human hepatitis A virus. Proc Soc Exp Biol Med (1977) 0.94
Jeryl Lynn strain live mumps virus vaccine. Durable immunity for three years following vaccination. JAMA (1969) 0.93